• Biovica issued a correction to its Oct. 6 share issue memorandum to clarify its patent position for DiviTum TKa.
• DiviTum TKa uses an ELISA platform, not the PCR-based technology previously described as covering the current commercial product.
• The ELISA-based assay patent family expired in 2026; PCR-based patents expiring in 2031 relate to separate technology acquired in 2017.
• Competitive position is now framed around know-how, FDA 510(k) clearance, US reimbursement, clinical evidence, backed by immuno-oncology use patents.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biovica International AB published the original content used to generate this news brief on October 12, 2026, and is solely responsible for the information contained therein.